Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.61 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.31 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30789126 | 1.00 | GRM2 (0.61) | GRM2USP7OPRL1PLATSOS1 | |
| SCHEMBL2612606 | 1.00 | GRM2 (0.61) | GRM2USP7OPRL1PLATSOS1 | |
| SCHEMBL2122944 | 1.00 | GRM2 (0.61) | GRM2USP7OPRL1PLATSOS1 | |
| SCHEMBL15098092 | 0.88 | GRM2 (0.54) | GRM2OPRL1MAPK1KDM4EALDH1A1 | |
| SCHEMBL30789127 | 0.87 | GRM2 (0.78) | GRM2OPRL1PLATSOS1KCNH2 | |
| SCHEMBL2123824 | 0.87 | GRM2 (0.78) | GRM2OPRL1PLATSOS1KCNH2 | |
| SCHEMBL8122370 | 0.87 | GRM2 (0.47) | GRM2USP7SOS1KCNH2MAPK1 | |
| SCHEMBL8122366 | 0.87 | GRM2 (0.47) | GRM2USP7SOS1KCNH2MAPK1 | |
| SCHEMBL2123310 | 0.87 | GRM2 (0.47) | GRM2USP7SOS1KCNH2MAPK1 | |
| SCHEMBL2123528 | 0.83 | GRM2 (0.64) | GRM2OPRL1PLATKCNH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377939-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| US-8377939-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| US-8377940-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| US-8377940-B2 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842 | ASTRAZENECA AB (SE) | 2013-02-19 | — | — | US | disclosed |
| EP-2167502-B1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2444399-A1 | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators - 842 | AstraZeneca AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| US-20100267740-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| US-20100267740-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 | ASTRAZENECA AB (SE) | 2010-10-21 | — | — | US | disclosed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008150233-A1 | OXADIAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - 842 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306077-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators 842 | GRM1, GRIN1, GRM2 | GRM2 3/4885USP7 3477/4885OPRL1 106/4885 |
| US-20100267740-A1 | Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842 | GRM1, GRM2, GRIN1 | GRM2 2/4885USP7 3491/4885OPRL1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.